Compared to other recessive disorders, MUTYH-associated Polyposis is unusual in that:
For reproductive partner testing, we propose that:
Regarding extent of testing, we propose:
Further information is available in the statement and manuscripts here below and here.
The identification of germline pathogenic variants in MBD4 presents challenges for variant reporting, genetic counselling and clinical management, particularly given the differing implications of heterozygous and biallelic variants. Biallelic pathogenic variants are associated with MBD4-associated neoplasia syndrome, whereas current evidence does not support a clinically actionable increase in cancer risk for heterozygous carriers.
This UKCGG statement provides pragmatic recommendations to support consistent reporting and management of germline MBD4 variants. It addresses the clinical implications of heterozygous and biallelic findings, considerations around reproductive partner testing, and the importance of appropriate interpretation in the context of the individual's phenotype and family history.
The statement aims to promote consistency across clinical and laboratory practice, while recognising the limitations of the current evidence and the need to review recommendations as further data emerge.
Loading...